Clinical trial in type 1 diabetes with Diamyd Medical's Remygen® is fully recruited
The investigator-initiated clinical trial ReGenerate-1 in type 1 diabetes with Diamyd Medical's investigational drug Remygen[®] (GABA) is now fully recruited with 35 patients. The participants will be followed for up to 9 months. Results are expected to be presented in the first quarter of 2023.“ReGenerate-1 includes patients who have had type 1 diabetes for many years,” says Per-Ola Carlsson, Professor at Uppsala University and Uppsala University Hospital, Sponsor of the trial. “The interest in participating has been great, and this is probably due to the fact that the trial is aimed at